Pharmafile Logo

global access

- PMLiVE

Origins’ Knowledge Centre

A collection of resources including webinar recordings, publications and short videos to help you be more patient focussed

Origins – The Patient Focused Specialists

- PMLiVE

Positive results for Almirall’s lebrikizumab in atopic dermatitis published in NEJM and BJD

The common inflammatory skin disease affects over 4% of adults in the EU

- PMLiVE

Bristol Myers Squibb’s Sotyktu approved by EC for plaque psoriasis

At least 100 million people worldwide are impacted by some form of psoriasis

- PMLiVE

Time to talk about health inequalities

Health inequalities are increasingly being recognised as a crucial healthcare challenge in the UK

Powering Rapid Cognitive Analysis with AI

Dr. Tom Sawyer, CFO at Cognetivity Neurosciences, discusses the benefits of AI-driven dementia detection technology for patients, health care providers, and clinical research.To find out more about Impetus: https://www.meetwithimpetus.comImpetus Digital...

Impetus Digital

- PMLiVE

AstraZeneca and Amgen’s Tezspire recommended by NICE for severe asthma

An estimated 98,000 patients with severe uncontrolled asthma may be eligible for the new treatment

- PMLiVE

Healthware Group report on depression care in Italy highlights need for digital therapeutics

Mental health disorders are the fifth leading cause of disability adjusted life years in Italy

- PMLiVE

Masking the truth

Why a not-so-good editorial piece from The New York Times has me a little vexed

The speed of science and the pace of comms

Pharma red tape slows comms but there is a solution, Paul Hutchings, founder of fox&cat, writes.

Fox&Cat

- PMLiVE

MSD’s Keytruda to be made available in England for advanced cervical cancer patients

Around 2,600 people are diagnosed with cervical cancer each year in England

- PMLiVE

Eli Lilly increases investment to almost $1bn for new Irish manufacturing facility

The biologics manufacturing site is expected to create more than 300 highly skilled jobs

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links